I S FA

10th International Society for Apheresis Congress

13 – 16 May 2015 | Cancún, Mexico

ProgramParagonGroup

ISFA 2015 | www.isfacongress.com
Paragon Group - www.paragong.com
18 Avenue Louis-Casai , 1209 Geneva , Switzerland
Email: secretariat@isfacongress.com

Table of Contents
Welcome Message ............................................................. 3
Organization and Invited Speakers ............................. 4
General Information .......................................................... 5
Supporting Partners ......................................................... 6
Sponsors ................................................................................ 7
Scientific Program
Wednesday, 13 May 2015 ................................... 13
Thursday, 14 May 2015 ........................................ 14
Friday, 15 May 2015 ............................................... 18
Saturday, 16 May 2015 ......................................... 22
Abstracts ................................................................................ 29
Author Index ........................................................................ 67

2

I S FA

Welcome message from Congress President
Dear Colleagues
On behalf of International Society for Apheresis (ISFA), it is my honor towelcome you to the 10th ISFA Congress in Cancun, Mexico.
Our main objective for the 2015 ISFA Congress is to present the most current
technologies and their clinical applications in the field of apheresis. This year,
ISFA will collaborate with the Asociacion Mexicana de Medicina Transfusional
AC (AMMTAC). With the help of AMMTAC President, Dr. Angel Guerra-Marquez,
our aim is to advance the science of transfusion and apheresis medicine.
This year’s Congress includes an international group of speakers who will focus
on such topics as Atherosclerosis, Immunology, Inflammation, Nephrology,
Infectious Disease/Sepsis, Regulatory Issues, Cardiology and Hepatology.
In addition, AMMTAC will present and address issues in the field of transfusion
medicine such as blood borne diseases, blood donation, and safety.
We hope that you will be able to attend our scientific congress and takepleasure in the communal activities that we have planned. On the first day,the welcome reception will provide a chance for all of those participating tomeet and enjoy an evening of entertainment. There will also be plenty of timeto enjoy the incredible natural scenery and culture that Cancun has to offer.
We look forward to welcoming you to Cancun for the Congress in 2015.
Warm regards,

Patrick M. Moriarty
President, ISFA

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

3

Organization
The Officers and the Board of Trustees 8th Term (2013-2015)
The Officers:
President

Secretary Treasurer

President-Elect

Editor-in Chief

P. Moriarty (USA)W. Szpirt (Denmark)Immediate Past-President
T. Tani (Japan)

Vice President

A. Torloni (USA)A. Casian (UK)M. Yonekawa (Japan)

Invited Speakers
Georg Boehmig
Alina Casian
Yoshihiro Endo
Siami Ghodrat
Bernd Hohenstein
Beate R. Jaeger
Andre Kaplan
Jan KielsteinHans-Ulrich Kloer
Rudolf Kunze
Hisashi Makino
Paul Malchesky
Steffen Mitzner
Jody Olson

4

Y. Endo (Japan)

T. Akizawa (Japan)
Regional Offices
America: P. Malchesky,
P. Moriarty, A. Torloni
Europe: K. Derfler, J. Klinkmann, V. Witt
Pan-Pacific: H. Tsuda, K. Lin, D. Kong

Christian Peter
Wolfgang Ramlow
Ahmed Sheriff
Wladimir Szpirt
Sotirios Tsimikas
James Underberg
Jörg Vienken
Uwe Wallstab
Grit Waitz
Robert WeinsteinHeinz Wiendl
Anne Winkler
Jeffrey Winters
Volker WittI S FA

General Information
Venue

Cancun Center Conventions & Exhibitions
Boulevard Kukulcan KM. 9 1er Piso, Zona Hotelera, 77500
Canun, Mexico
Tel: +52 998 881 0400

Language

The official language of the congress is English

Registration & Hospitality Desk

The Registration desk will operate throughout the meeting in the foyer of theConventions Center of the hotel at the following hours:
May 13, 2015
15:00-19:00 hrs
May 14, 2015
08:00-17:00 hrs
May 15, 2015
08:00-17:00 hrs
May 16, 2015
08:00-13:00 hrs

E-posters

The E-posters will be presented throughout the congress at the specific E-poster
stations.

Get together Reception

A reception will be held on the evening of Wednesday, May 13, 2015, at the Fiesta
Americano Coral Hotel, Cancun.

Congress Organizers:

ParagonGroup

ISFA 2015 | www.isfacongress.com
Paragon Group - www.paragong.com
18 Avenue Louis-Casai , 1209 Geneva , Switzerland
Email: secretariat@isfacongress.com

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

5

COLLABORATING ASSOCIATIONS
Belgian Hematological Society
British Blood Transfusion Society
Canadian Apheresis Group
Czech Oncological Society
Danish Society of Nephrology
European Renal Association European Dialysis and Transplant Association
FH Foundation
Israel Society of Hematology and Blood Transfusion
National Lipid Association
Sociedad Chilena de Hematología
Sociedad Peruana de Oncologia Medica
Sociedad Venezolana de Hematologia
Sociedad Venezolana de Oncología
Sociedade Brasileira de Nefrologia
Società Italiana di Nefrologia
The Peruvian Society for Medical Oncology
World Apheresis Association

Endorsment

European Renal Association- European Dialysis and Transplant Association

MEDIA PARTNERS

Artificial Organs
Haematologica
Therapeutic Apheresis and Dialysis

6

I S FA

Sponsors
Gold Sponsor

Silver Sponsor

Additional Sponsors

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

7

Sponsors
Fresenius
Fresenius Medical Care is the world’s largest fully integrated provider of products
and services for individuals undergoing dialysis due to chronic kidney failure.
Through its network of more than 3,000 dialysis clinics in North America, Europe,
Latin America, Asia-Pacific, and Africa, Fresenius Medical Care provides dialysis
treatments for 250,000 patients around the globe.
Therapeutic Apheresis, a division of Fresenius Medical Care, is dedicatedto provide extracorporeal treatments to patients in whom standard therapy
approaches have unfortunately failed. For instance, harmful pathogenic autoantibodies produced by the patient’s own metabolism occur in many clinicalsettings such as various autoimmune diseases or as responses to transplanted
organs. But also genetically impaired high levels of blood cholesterol are a typicalindication for Therapeutic Apheresis. As a principle mode of work, Therapeutic
Apheresis can be applied to adsorb these pathogens from the patient’s blood
through the use of selective adsorber columns. This kind of treatment can be
performed in repetitive modes in acute or chronic conditions. The advantageof this treatment is the pronounced selective removal of pathogens while thebeneficial metabolic particles are retained at the patient’s blood.
Immunosorba® and GLOBAFFIN® from Fresenius Medical Care are two specificadsorber columns for the treatment of immunoglobuline “G” mediated diseases.
They are mainly used for the treatment of autoimmune diseases and antibody
mediated transplant rejections (e.g. DCM, Pemphigus, MG, GBS, SLE, AHR).
In patients suffering from severe hypercholesterolaemia, the only effective
therapy option to reduce LDL-C and Lp(a) significantly is the lipoprotein apheresis
technology with e.g. the apheresis adsorber DALI® or double filtration system
MONET®. With these innovative therapeutic apheresis treatments, FME defines
highest standards of care in the treatment of critically sick patients.

Best Theratronics Ltd
Best Theratronics is the world’s leading manufacturer of blood and research
irradiators. Offering both gamma and x-ray, we have a long history of reliability,
support and high-quality products. The Gammacell 1000 and 3000 prevents graftversus-host disease and are considered the “Gold Standard” in countless clinics
worldwide. Our Raycell Mk2 dual x-ray tubes deliver unparalleled dose uniformity
across its 2.0 and 3.5 litre canisters. The Gammacell 40 Exactor is the industry’s
preferential irradiator, making it a welcome addition to research labs. For more
information please visit: www.theratronics.ca.

8

I S FA

Sponsors (CONT.)
ISIS Pharmaceuticals
ISIS is exploiting its leadership position in RNA-targeted technology to discoverand develop novel drugs for its product pipeline and for its partners. Isis’ broad
pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasison cardiovascular, metabolic, severe and rare diseases, including neurologicaldisorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product,
KYNAMRO®, in the United States and other countries for the treatment of patientswith homozygous FH. Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases. These include ISIS-APOCIIIRx, a drug Isis
is developing and plans to commercialize through its wholly owned subsidiary,
Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome
and partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat
patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis;
and ISIS-SMNRx, a drug Isis is developing with Biogen Idec to treat infants andchildren with spinal muscular atrophy, a severe and rare neuromuscular disease.
Isis’ patents provide strong and extensive protection for its drugs and technology.
Additional information about Isis is available at www.isispharm.com.

Kaneka Medical Products
Kaneka Corporation is touching the lives of people all over the world with infinite
possibilities of chemistry. By further advancing our key of highly innovativetechnology in producing medical devices and building blocks for active
pharmaceutical ingredients (API), macromolecules, fermentation and bioscience,
Kaneka is exploring new possibilities beyond the traditional boundaries ofchemistry.
Kaneka Pharma Europe N.V. (KPE) is the independent subsidiary for the European
market. Lipoproteinapheresis (La(a), LDL), in which Kaneka is one of the pioneers
since 1989, is beside the interventional products one of KPE’s main business.

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

9Sponsors (CONT.)
Kaneka Pharma America

Kaneka Pharma America LLC is a wholly owned subsidiary of Kaneka Corporation.
Our main offices are located in New York City, NY. We are the exclusive distributorof the Liposorber System in the United States and Canada.
The Liposorber® System has been approved by the FDA for patient use since 1996.
Liposorber® is intended for FH patients for whom at least six months of diet andmaximum drug therapy has been either ineffective or not tolerated along with:· LDL-C > 500 mg/dl (Homozygotes)· LDL-C ≥ 300 mg/dl (Heterozygotes) or· LDL-C ≥ 200 mg/dl with documented CHD (Heterozygotes)

Nikkiso
NIKKISO is well-known for providing extracorporeal technologies and products
which meet the demands of the customers, patients, society and the modern
times. Nikkiso is recognized as precision machinery company in the field of blood
purification and hemodialysis. Beside our huge expertise in the development andproduction medical equipment, our R&D team has developed a new Cytapheresis
Adsorber (Immunopure®) for the treatment of Ulcerative Colitis patients. For theeasy use of this Cytapheresis Adsorber a blood pump has been developed.
Based in Hanover/Germany NIKKISO Europe GmbH is responsible for the
distribution of the NIKKISO products in the EMEA region.

Synageva

Synageva is a biopharmaceutical company focused on the discovery,
development, and commercialization of therapeutic products for patients withrare diseases. The company’s pipeline programs consist of protein therapeutics
for rare diseases with unmet medical need at various stages of development
including the lead program, Kanuma™ (sebelipase alfa) for lysosomal acid lipase
deficiency (LAL D), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB, also known
as Sanfilippo B syndrome), and SBC-105 for generalized arterial calcification of
infancy (GACI) and other rare calcification diseases.

10

I S FA

Scientific
ProgramWednesday, May 13, 2015
17:30-21:30

Opening Key Note Address
Chairperson: QFB Clotilde Estrada Carsolio ; Dr. Patrick MoriartyGrand Cancun 4, 5A

17:30

Global Challenges in Blood Donation
Paul Strengers, Sanquin Blood Supply Foundation, The Netherlands
Recognition to a Life in Transfusion Medicine
Opening Ceremony
100 years of Plasmapheresis
Siami Ghodrat
Vanderbilt School of Medicine, USA
Get Together Reception

18:15
18:45
19:00

19:30

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

13

Thursday, May 14, 201508:30-09:15

Plenary Session: 1
Chairperson: Dr. Wolfgang Ramlow, Germany Grand Cancun 4, 5A

08:30

Apheresis Technologies: Procedures and Equipment for
Selective Target Removal
Uwe H. Wallstab, Engineering Office for Medical Technology, Germany

09:15-10:00

Plenary Session: 2
Chairperson: Dr. Ángel Guerra Márquez 

09:15

Use of Blood Components Based on the Recommendations of
the Holland Blood Transfusion Conference
Dr. Paul Strengers

10:00-10:30

Plenary Session: 3
Chairperson: Dra Fany Rosenfeld Mann

10:00

Microquimerismo Fetal Y MaternoÁngel Guerra Márquez, Mexico

10:30-11:00

Tea/Coffee Break and Exhibition Viewing 

11:00-13:00

Breakaway Session: Inflammatory Markers and Apheresis,
Chairpersons: Dr. Patrick Moriarty, USA; Dr. Beate R. Jaeger, GermanyGran Cancun 5

11:00

Current Status and Future Perspectives of Lp(A) Apheresis
Beate R. Jaeger, Germany
Galectin-3 Removal and Apheresis
Isaac Eliaz, Econugenics, USA
Dynamics of Coronary Atherosclerosis in Post-CABG Patients
Receiving Lipoprotein Apheresis
Adzhiev Renad, Russia
H.E.L.P.-Apheresis in Hypertensive Disorders of Pregnancy
C. Contini1,4; B. König1; F. Markfeld-Erol2; M. Kunze2; S. Zschiedrich3;
H. Prömpeler2; G. Pütz1; K. Winkler1
1
Institute of Clinical Chemistry and Laboratory Medicine, University
Hospital Freiburg
2
Department of Obstetrics and Gynaecology, University Hospital Freiburg
3
Renal Division, Department of Medicine, University Hospital Freiburg
4
Hermann Staudinger Graduate School, University Freiburg

11:30
12:00

12:30

14

Grand Cancun 4, 5A

Grand Cancun 4, 5A

Exhibition Foyer

I S FA

Thursday, May 14, 2015 (COnt.)
11:00-13:00

Breakaway Session: Technology
Chairpersons: Dr. Paul Malchesky, USA ; Dr. Joerg Vienken, GermanyCozumel 5

11:00

Membrane Technologies for Plasma Separation and Therapeutic
Plasma Filtration
Paul Malchesky, International Center for Artificial Organs andTransplantation, USA
Basic Principles of Adsorption in Life Sciences
Joerg Vienken, Nephro-Solutions AG, Germany
Photopheresis – Current Status And Perspectives In
Immunologically Driven Conditions
Volker Witt, St. Anna Kinderspital, Austria
Regulatory Process for Medical Devices in Europe: Current Status
and Upcoming Revised Regulations
Uwe H. Wallstab1, Jens Grothues2
1
Engineering Office Medical Technology U.WALLSTAB, Germany
2
RegDev Ltd, UK

11:30
12:00

12:30

13:00-14:00

Lunch Break

14:00-15:30

Breakaway Session: Nephrology
Chairpersons: Dr. Wladimir Szpirt , Denmark ; Dr. Andre Kaplan, USAGran Cancun 5

14:00

Plasma Exchange in ANCA+ Vasculitis with Renal Involvement
Wladimir Szpirt, Rigshospitalet, Denmark
Plasma Exchange for Alveolar Hemorrhage in Vasculitis
Alina Casian, Guy’s and St Thomas’ NHS Foundation Trust, UK
Apheresis for Renal Disease: Current Status
Andre Kaplan, University of Connecticut Health Center, USA

14:30
14:00

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

15

Thursday, May 14, 2015 (COnt.)
14:00-15:00

Breakaway Session: Apheresis in Critical Care,
Chairperson: Dr. Jan Kielstein, Germany; Dr. Steffen Mitzner, GermanyCozumel 5

14:00

Extracorporeal Therapy in Liver Disease, Current Strategies andFuture Directions
Jody Olson, University of Kansas Medical Center, USA
What To Be Learned From Two Decades Of MARS Treatment In
Liver Failure Patients?
Steffen Mitzner, Biomedical Research Center Rostock, Germany
Membrane vs. Centrifuge Based Therapeutic Plasma
Exchange – A Randomized Prospective Crossover Study
Jan Kielstein, Medical School Hannover, Germany

14:30

15:00

15:30-16:00

Tea/Coffee Break and Exhibition Viewing

16:00-17:30

Breakaway Session: Abstracts
Chairperson: Dr Siami Ghodrat, USA; Dr. Alina Casian, UKGran Cancun 5

16:00

Apheresis for Pediatric DCM
Takeshi Moriguchi, Kenichi Matsuda, Norikazu Harii,
Junko Goto, Masahiko Yanagisawa, Daiki Harada,
Sugawara Hisanori, Minako Hoshiai, Keiichi Koizumi
University of Yamanashi School of Medicine, JapanTo Assess the Incremental Cost Effectiveness of Treating Guillain
Barre Syndrome Patient with Intravenous Immunoglobulin as
Compared to Therapeutic Plasma Exchange
Ratti Ram Sharma, Ashish Maheshwari, Manish Modi,
Navneet Sharma, Shankar Prinja, Rekha Hans,
Neelam Marwaha, Rekha Hans, Neelam Marwaha
Postgraduate Institute of Medical Education and Research, India
A Novel Vascular Access Route for Granulocyte Monocyte
Apheresis – Puncture of Accompanying Veins of Brachial Arteryunder Ultrasonographic Guidance
Norio Hanafusa, Toshihiro Torato, Daisuke Katagiri, Tomoko Usui,
Akihiko Matsumoto, Eisei Noiri, Masaomi Nangaku
The University of Tokyo Hospital, Japan

16:15

16:30

16

Exhibition Foyer

I S FA

Thursday, May 14, 2015 (COnt.)
16:45

17:00

17:15

Plasmapheresis of Pegylated Liposomal Doxorubicin: A New
Approach to Reduce Toxicity during Chemotherapy (CARL-Trial)
Stefan Zschiedrich1, Jürgen Eckes1, Oliver Schmah2, Beate Rautenberg1,
Annette Hasenburg1, Karl Winkler1, Gerhard Pütz1
1
University Medical Center Freiburg, Germany
2
Caritas Klinikum Saarbrücken, Germany
The Use of Vortex Port for Red Cell Exchange in Sickle Cell
Disease Patient: Pilot Study
Lydia Alexander, Imperial College Healthcare NHS Trust, UK
The Immature Fraction of Platelets in Donor’s Peripheral Blood
Plateletapheresis
Valery Pogorelov1,2, Victoria Ufimceva1, Lyudmila Ivanova1,
Beksoltam Urtaev2, Igor Buchtijrov1
1
Research Institute of Occupational Health the Russian Academy ofMedical Sciences, Russia
2
Moscow State University of Medicine and Dentistry, Russia

16:00-17:30

Breakaway Session: Transplantation
Chairperson: Dr. Jan Kielstein, Germany; Dr. Georg Boehmig, Austria

Cozumel 5

16:00

The Role Apheresis Treatment before and after Kidney
Transplantation
Georg Boehmig, Medical University of Vienna, Austria
Prolonging Survival after Orthotopic Heart Transplantation by
Means of HELP Apheresis
Beate Jaeger, Germany
Intra-operative Therapeutic Plasma Exchange during Heart
Transplant Surgery
Ramakrishna Reddy, Sandy Bruning
Midwest Region, USA

16:30

17:00

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

17

Friday, May 15, 201508:30-09:15

Plenary Session 4:
Chairperson: Dr. Wladimir Szpirt, Denmark

08:30

ICE – A Novel Extracorporeal System for Treatment of Septic
Patients Utilizing Immobilized Granulocytes
Steffen Mitzner, Biomedical Research Center Rostock, Germany

09:15-10:00

Plenary Session 5:
Chairperson: Dr Volker Witt, Austria

09:15

The Role of Apheresis in the Treatment of Ebola Virus Disease
Anne Winkler, Emory Special Coagulation Laboratory, USA

10:00-10:45

Plenary Session 6:
Chairperson: Dra. Adolfina Bergés García

10:00

Síndrome Hiperhemolítico. Etiopatogenia Y Manejo Terapéutico
Graciela León de González

10:45-11:30

Tea/Coffee Break and Exhibition Viewing

11:30-13:00

Breakaway Session: Immune Apheresis
Chairperson: Dr. Jeffrey Winters, USA; Dr. Siami Ghodrat, USAGran Cancun 5

11:30

Apheresis in the Treatment of Idiopathic Dilated Cardiomyopathy
Jeffrey Winters, Mayo Clinic, USA
Agonistic Autoantibodies to Adrenoceptors, PathophysiologicalRole and Therapy
Rudolf Kunze, Germany
Double Column Immunoadsorption – An Effective Therapeutic
Option in Immune Mediated Diseases
Bernd Hohenstein
Extracorporeal Treatment and Lipoprotein Apheresis Center, Germany

12:00

12:30

18

Grand Cancun 4, 5A

Grand Cancun 4, 5A

Grand Cancun 4, 5A

Exhibition Foyer

I S FA

Friday, May 15, 2015 (cont.)
11:30-13:00

Breakaway Session: Dyslipidemias
Chairperson: Dr. Beate R. Jaeger, Germany; Dr. Hans-Ulrich Kloer, GermanyCozumel 5

11:30

KISS – A Cardiometabolic Risk Assessment Tool to Identify
Dyslipidemic High-Risk Cardiovascular Patients in Daily Routine
Wolfgang Ramlow, Apheresis Center Rostock, Germany
Cross-Over Study Comparing the Liposorber Whole Blood andPlasma Lipid Apheresis System for Optimizing the Individual
Therapy of Patients with Cardiovascular Disease and Severe
Dyslipidemia
Grit Waitz, BioArtProducts GmbH, Germany
Severe Hypertriglyceridemia – An Indication for Apheresis Treatment
Hans-Ulrich Kloer, Germany

12:00

12:30
13:00-14:00

Lunch Break

14:00-15:30

Breakaway Session: Immune Apheresis
Chairperson: Dr. Bernd Hohenstein, Germany; Dr. Nico Melzer, GermanyGran Cancun 5

14:00

Immunoadsorption In Neurological Diseases – An Effective
Treatment Tool
Nico Melzer, Germany
A Possible Role for Immunoadsorption Treatment in
Alzheimer’s Diseases
Rudolf Kunze, Germany
Immunopure Cytapheresis: In Vitro Evaluations and First
Clinical Results
Grit Waitz1, Matthias Schneider2, Heinrich Prophet2, Wolfgang Ramlow2
1
BioArtProducts GmbH, Germany
2
Apheresis Center Rostock, Germany

14:30

15:00

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

19

Friday, May 15, 2015 (cont.)
14:00-15:30

Breakaway Session: Dyslipidemia Continued
Chairperson: Dr. Hans-Ulrich Kloer, Germany; Dr. Patrick Moriarty, USA
Cozumel 5

14:00

Lysosomal Acid Lipase Deficiency – An Unrecognized Causeof Dyslipidemia
James Underberg, Bellevue Hospital Lipid Clinic, USA
Rheological Improvement In Lipid Apheresis –More than a Pleiotropic Effect?
Patrick Moriarty, University of Kansas Medical Center, USA
Treatment of Pad with Apheresis
Hisashi Makino, National Cardiovascular Center, Japan

14:20

14:50
15:30-16:00

Tea/Coffee Break and Exhibition Viewing

16:00-18:00

Breakaway Session: PCSK9Chairperson: Dr Patrick Moriarty, USA; Dr Bernd Hohenstein, GermanyGran Cancun 5

16:00

Overview of PCSK9 and the Effect of Lipoprotein Apheresis
on PCSK9 Levels
Bernd Hohenstein, Extrakorporeal Treatment and Lipoprotein
Apheresis Center, Germany
PCSK9 Inhibitors for Patients with Statin Intolerance (Alternative Trial)
Patrick Moriarty, University of Kansas Medical Center, USA
FH Patients Receiving Lipoprotein Apheresis (Escape Trial)
Patrick Moriarty, University of Kansas Medical Center, USA

16:30
17:00

Exhibition Foyer

16:00-18:00

Breakaway Session: Sepsis
Chairperson: Yoshihiro Endo, Japan; Dr. Steffen Mitzner, GermanyCozumel 5

16:00

Membrane vs. Centrifuge Based Therapeutic Plasma
Exchange – A Randomized Prospective Crossover Study
Jan Kielstein, Medical School Hannover, Germany
The Efficacy of Direct Hemoperfusion with Polymyxin B
Immobilized Fiber Column in Patients with Severe Sepsis and
Septic ShockYoshihiro Endo1, Tomoharu Shimizu1, Tohru Tani2
1
Shiga University of Medical Science, Japan
2
Biomedical Innovation Center, Japan

16:30

20

I S FA

Friday, May 15, 2015 (cont.)
17:00

17:30

Uncovering Complement-Mediated Thrombotic Microangiopathy
in the Setting of Sepsis, Colitis, and Progressive Renal Failure
Jan Hofmann1, Dobri D. Kiprov2
1
Apheresis Care Group, USA
2
California Pacific Medical Center, USA
Analysis of Relationship between Central Venous Pressure andHemodynamic Effect of Polymyxin-B Direct Hemoperfusion for
Septic Shock Patients
Hiroyuki Yamada, Tatsuo Tsukamoto, Motoko Yanagita
Graduate School of Medicine, Kyoto University, Japan

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

21

Saturday, May 16, 201508:30-09:15

Plenary Session 7
Chairman: Dr. Wolfgang Ramlow, Germany

08:30

Antisense Therapy Directed to Lp(A) For Lp(A)-Eligible
Apheresis Patients
Sotirios Tsimikas, ISIS Pharmaceuticals, USA

09:15-10:00

Plenary Session 8
Chairperson: Dr. Rudolf Kunze, Germany

09:15

Removal of C-reactive protein through Adsorption Techniques
for Therapy of Myocardial Infarct and Stroke
Ahmed Sheriff2, Ralf Schindler1, Birgit Vogt2, Rudolf Kunze3,
1
Charité University Medicine Berlin, Germany
2
Pentracor GmbH, Germany
3
MDC Berlin, Germany

10:00-10:45

Plenary Session 9
Chairperson: Dra. Malva H. Mejía Arregui

10:00

Utilidad de Biomarcadores Para Predecir Rechazo en Trasplante
Renal y Estrategias de Desensibilización
EBC. Julio César Martínez Álvarez

10:45-11:30

Tea/ Coffee Break and Exhibition Viewing

11:30-13:00

Breakaway Session: Regulatory Issues / Guidelines / Registers
Chairperson: Dr. Beate R. Jaeger, Germany; Dr. Joerg Vienken, GermanyGran Cancun 5

11:30

Clinical Registers as Useful Tools to Improve the Data Base for
Apheresis Treatments
Christian Peter1,2, Thomas Zimmermann1, Wolfgang Ramlow1,3
1
BioArtProducts, Germany
2
Fraunhofer Institute for Cell Therapy and Immunology, Germany
3
Apherese Center, Germany
The German Lipid Apheresis Guidelines – A Good Basis forInternational Harmonization
Wolfgang Ramlow, Apheresis Center Rostock, Germany
An International Dyslipidemic Register - Ready To Go
Christian Peter1, Thomas Zimmermann1, Wolfgang Ramlow1,2
1
BioArtProducts, Germany
2
Apherese Center, Germany

12:00

12:30

22

Grand Cancun 4, 5A

Grand Cancun 4, 5A

Grand Cancun 4, 5A

Exhibition Foyer

I S FA

Saturday, May 16, 2015
11:30-13:00

Breakaway Session: Other Indications
Chairperson: Dr. Robert Weinstein, USA; Dr. Dobri Kirpov, USA
Cozumel 5

11:30

Unusual Indications for Therapeutic Leukapheresis in
Hematological Malignancies
Robert Weinstein, University of Massachusetts Medical School, USA
Heterochronic Intermittent Plasma Exchange for the Preventionof Cellular Senescence
Dobri Kiprov, USA
Challenges for Apheresis Professionals in the Age of Emerging
Cellular Therapies
Regina Rohe, USA

12:00

12:30

13:30-14:30

Congress ClosingGrand Cancun 4, 5A

14:30-15:30

ISFA General Assembly

Grand Cancun 4, 5A

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

23

E Posters
1.	Effects of Single-pass Albumin Dialysis (SPAD) in Patients with Acuteon Chronic Liver Failure (AoCLF) after Cardiac Surgery Intervention
Assem Nogaibayeva1, Bolat Bekishev1, Fatikh Kacheganov1, Timur Kapyshev1,
Assel Medressova1
1
National Research Cardiac Surgery Centre, Kazakhstan
2.
TTP-like Syndrome Associated with Infectious Diseases:
Pathogenesis and its Implication on Potential Treatment with
Therapeutic Plasma Exchange (TPE)Jae Chang
University of California Irvine School of Medicine, USA
3.	Efficacy of the MICA Antibody for Transplant PatientsJin A Mo
National Evidence-based Health Care Collaborating Agency, South Korea
4.
Plasma Levels of Coronary Risk Biomarkers in Chronic Kidney
	Disease Patients under Maintenance Hemodialysis Treatment
Koichiro Homma1, Yasuhiko Homma2, Joe Yoshizawa1, Shingo Hori1
1
Keio University, Japan
2
Tokai University, Japan
5.	Agglutination due to Cold Antibodies during Plasmapheresis in a
Healthy Donor
Niubel Diaz Padilla, Fernando Gonzalez García, Arlinke Bokhorst
Sanquin Blood Supply, The Netherlands
6.	Effectiveness of the ST2 Test: Systematic Reviews
Soyoung Kim
National Evidence-based Collaborating Agency, South Korea
7.	Side Effects during Protein A Immunoadsorption
Rafael Ponikvar, Laura Poljancic, Jakob Gubensek, Andreja Marn Pernat,
Vladimir Premru, Bojan Knap, Miha Benedik, Ana Zupunski Cede,
Jadranka Buturovic Ponikvar
University Medical Center Ljubljana, Slovenia
8.
Citrate Anticoagulation Instead of Heparin in Primary Plasmapheresis
Circuit of Protein a Immunoadsorption
Rafael Ponikvar1, Jakob Gubenšek1,2, Andreja Marn Pernat1,
Bojan Knap1, Vladimir Premru1, Jadranka Buturović Ponikvar1,2
1
University Medical Center Ljubljana, Slovenia
2
University of Ljubljana, Slovenia

24

I S FAE Posters (COnt.)
9.

Plasma Exchange Plus Continuous Hemofillration and Hemoperfusion
for the Patients with Acute Toadstool Poisoning and MODS
Xin Lin, Ying Xie, Jing Yuang, Yan Zha
The People’s Hospital of Guizhou Province, China

10th International Society for Apheresis Congress
13 – 16 May 2015 | Cancún, Mexico

25